Long-term evaluation of antimalarials in a Dutch SLE cohort: Intolerance and other reasons for non-use

Clinical and Experimental Rheumatology

Volumn 32, Issue 1, 2014, Pages 95-100

  Tsang A Sjoe, Michel W P ^a   Bultink, Irene E M ^a   Voskuyl, Alexandre E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antimalarials; Cohort studies; Drug dosage calculations; Hydroxychloroquine; Systemic lupus erythematosus

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ATTITUDE OF HEALTH PERSONNEL; BODY WEIGHT; CHI-SQUARE DISTRIBUTION; DRUG DOSAGE CALCULATIONS; DRUG UTILIZATION REVIEW; FEMALE; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYDROXYCHLOROQUINE; LOGISTIC MODELS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894025614     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. RUIZ-IRASTORZA G, KHAMASHTA MA: Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 2008; 17: 271-3.
2. COSTEDOAT-CHALUMEAU N, LEROUX G, PIETTE JC, AMOURA Z: Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? Joint Bone Spine 2010; 77: 4-5
3. TANG C, GODFREY T, STAWELL R, NIKPOUR M: Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 2012 July 25 [Epub ahead of print].
4. RUIZ-IRASTORZA G, RAMOS-CASALS M, BRITO-ZERON P, KHAMASHTA MA: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-8.
5. WALLACE DJ: Antimalarials - the 'real' advance in lupus. Lupus 2001; 10: 385-7.
6. BERTSIAS G, IOANNIDIS JP, BOLETIS J et al.: EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.
7. BERTSIAS GK, TEKTONIDOU M, AMOURA Z et al.: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
8. LEVY RA, VILELA VS, CATALDO MJ et al.: Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10: 401-4.
9. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991; 324: 150-4.
10. FESSLER BJ, ALARCON GS, McGWIN G, Jr et al.: Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473-80.
11. PETRI M, PURVEY S, FANG H, MAGDER LS: Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort. Arthritis Rheum 2012; 64: 4021-8.
12. RUIZ-IRASTORZA G, EGURBIDE MV, PIJOAN JI et al.: Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577-83.
13. WOLFE F, MARMOR MF: Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 775-84.
14. MAVRIKAKIS I, SFIKAKIS PP, MAVRIKAKIS E et al.: The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003; 110: 1321-6.
15. MARMOR MF, KELLNER U, LAI TY, LYONS JS, MIELER WF: Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118: 415-22.
16. MOSCA M, TANI C, ARINGER M et al.: Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011; 10: 383-8.
17. SUMPTER M, TATRO L, STOECKER W, RADER R: Evidence for risk of cardiomyopathy with hydroxychloroquine. Lupus 2012; 21: 1594-6.
18. SCHMAJUK G, YAZDANY J, TRUPIN L, YELIN E: Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 386-92.
19. FERNANDEZ M, MCGWIN G, JR, BERTOLI AM et al.: Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). Lupus 2006; 15: 700-4.
20. LERANG K, GILBOE IM, GRAN JT: Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus. Rheumatology (Oxford) 2012; 51: 663-9.
21. COSTEDOAT-CHALUMEAU N, AMOURA Z, HULOT JS et al.: Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3284-90.
22. COSTEDOAT-CHALUMEAU N, GALICIER L, AUMAITRE O et al.: Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2012 Jan 7 [Epub ahead of print].
23. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
24. JANMAHASATIAN S, DUFFULL SB, ASH S, WARD LC, BYRNE NM, GREEN B: Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
25. GLADMAN DD, IBANEZ D, UROWITZ MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-91.
26. GLADMAN D, GINZLER E, GOLDSMITH C et al.: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-9.
27. BULTINK IE, TURKSTRA F, DIAMANT M, DIJKMANS BA, VOSKUYL AE: Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26: 32-8.
28. PONS-ESTEL GJ, ALARCON GS, McGWIN G, Jr et al.: Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009; 61: 830-9.
29. DIJKMANS BA, LANDEWé RB, van den BORNE BE, BREEDVELD FC: Combination cyclosporine and (hydroxy)chloroquine in rheumatoid arthritis. Clin Exp Rheumatol 1999; 17 (Suppl. 18): S103-S104.
30. MOSCA M, BOUMPAS DT, BRUCE IN et al.: Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol 2012; 30 (Suppl. 73): S112-S115.